Waldenstrom’s Macroglobulinemia

Steven P. Treon, Giampaolo Merlini, Meletios Dimopoulos

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Waldenstrom’s macroglobulinemia (WM) is a lymphoid neoplasm resulting from the accumulation, predominantly in the marrow, of a clonal population of lymphocytes, lymphoplasmacytic cells, and plasma cells, which secrete a monoclonal immunoglobulin (Ig) M protein. WM presentation varies and can include cytopenias, as well as morbidity from the IgM paraprotein itself including peripheral neuropathy, cold agglutinemia, cryoglobulinemia, and hyperviscosity. Highly recurring mutations in MYD88 and CXCR4 are found in >90% and 30-40% of WM patients, respectively, and can impact disease presentation as well as therapy. MYD88 mutations trigger Bruton’s tyrosine kinase, a target of ibrutinib, while CXCR4 mutations contribute to drug resistance. Treatment with the monoclonal antibody rituximab alone or in combination with alkylators, proteasome inhibitors, or nucleoside analogues, as well as ibrutinib, is commonly used in the treatment of WM patients. Choice of treatment is impacted by goal of treatment, and avoidance of stem cell toxicity in younger autologous transplant-eligible WM patients.

Original languageEnglish
Title of host publicationNeoplastic Diseases of the Blood
PublisherSpringer International Publishing AG
Pages617-638
Number of pages22
ISBN (Electronic)9783319642635
ISBN (Print)9783319642628
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Bruton’s tyrosine kinase
  • CXCR4
  • Hyperviscosity
  • Ibrutinib
  • IgM
  • Lymphoplasmacytic lymphoma
  • MYD88
  • Rituximab
  • Waldenstrom’s macroglobulinemia

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Waldenstrom’s Macroglobulinemia'. Together they form a unique fingerprint.

Cite this